).
Supramolecular chemistry envisages the construction of novel materials and nanoscale devices ranging from molecular sensors to stimulus-responsive polymers (1, 2) . Spatial organization may be achieved either by templating (design from the top down) or through self-assembly of molecular components (bottom up). Connective tissue provides an example of the bottom-up design of a biomaterial based on hierarchical self-assembly of the collagen triple helix. Can such general principles be exploited in pharmacology? The present study explores the application of protein engineering (3) to the supramolecular chemistry of a therapeutic subcutaneous depot. Bottom-up control is accomplished by the pH-dependent binding of metal ions within self-assembled structures.
A model is provided by insulin, a protein containing two chains, A (21 residues) and B (30 residues) (Fig. 1A) (4) . The hormone is protected from misfolding in β-cells by Zn 2+ -stabilized assembly and microcrystallization (5) . Storage hexamers dissociate on secretion, enabling insulin to function as a dilute zinc-free monomer. Zn 2+ -stabilized hexamers are also employed in pharmaceutical formulations to delay insulin degradation (6) . Treatment of diabetes mellitus increasingly employs insulin analogs with altered pharmacokinetics (7) . Such pharmacokinetic "tuning" has enabled more effective glycemic control. Two classes of analogs extend the properties of wild-type formulations. More rapid-acting analogs are designed to limit self-assembly (8) or accelerate disassembly (9) . Longer-acting analogs are designed to promote self-assembly in the subcutaneous depot (10) or retard disassembly (11, 12) . These classes each exploit an inverse relationship between size of a subcutaneous protein complex and rate of capillary absorption (8, 9, 12) .
Although insulin is highly soluble at pH values > 7 or < 5, between these limits the protein reversibly undergoes isoelectric precipitation (13) . This property underlies the design of long-acting analog insulin glargine (the active ingredient of Lantus ® ) (12) . Its Bchain is extended by paired Arg residues (red in Fig. 1A , top) whose positively charged side chains shift the pI from 5.8 to 7.0 (11, 12) . Lantus is formulated at pH 4 as a clear unbuffered solution that, following subcutaneous injection, undergoes pHdependent precipitation to form a slow-release depot (11) . Insulin glargine exhibits increased cross-binding to the Type 1 insulin-like growthfactor receptor (IGF-1R) 1 , a homolog of the insulin receptor (IR) (12, 14 2 We present a new strategy for design of longacting depots: engineered "zinc staples" between protein assemblies. The essential idea envisaged a zinc-dependent switch between an insoluble subcutaneous depot and a soluble metabolic signal. To implement this strategy, paired His substitutions (Glu A4 →His and Thr A8 →His; Fig.  1A , bottom) were introduced at positions (i, i+4) of an α-helix (Fig. 1B) , thus recapitulating part of a Zn 2+ -binding site (17) . Such paired His elements are ubiquitous among classical Zn fingers (Supplemental Fig. S1 ). Positions A4 and A8 were chosen as sites of modification to avoid structural perturbation, preserve activity (18) , and maintain classical zinc assembly (4, 19) . Choice of this A-chain α-helix was further motivated by potentially favorable effects of its modification on the ratio of IR:IGF-1R binding (20, 21) . Zinc-stapled insulin hexamers exemplify a structure-based approach to the design of a subcutaneous protein depot. The analog's stringent receptor selectivity and supra-molecular assembly may enhance the safety and efficacy of insulin therapy.
Materials and Methods
Materials-Insulin was provided by NovoNordisk (DK). Insulin glargine was obtained from Lantus ® (Sanofi-Aventis, Paris, FR). Reagents for peptide synthesis were as described (22) .
Synthesis of Insulin Analog-Variant insulin chains were prepared by solid-phase synthesis (22) . Wild-type S-sulfonate B-chain derivatives were obtained by oxidative sulfitolysis of insulin (23) . Insulin analogs were prepared by chain combination and purified as described (22, 23) . The paired His A-chain substitutions were also incorporated into engineered monomer DKPinsulin (His B10 →Asp, Pro B28 →Lys, and Lys B29 →Pro) (24) . Yields were similar to that of wild-type insulin. Predicted molecular masses were confirmed by mass spectrometry.
Biochemical assays-Effects of the substitutions on pI relative to insulin and insulin glargine were measured by native isoelectricfocusing gel electrophoresis (Supplemental Methods online). Solubility was tested in dilute HCl (pH 4.0) in the presence of 0.52 mM ZnCl 2 , 185 mM glycerol, and 25 mM meta-cresol and on dilution into a buffered solution of 10 mM Tris-HCl (pH 6-9) and 140 mM NaCl by the method of DiMarchi and coworkers (20) (Supplemental Methods).
Crystallography-Crystals were obtained by hanging-drop vapor diffusion at room temperature in the presence of a 1:1.7 ratio of Zn 2+ to protein monomer and a 3.5:1 ratio of phenol to protein monomer in Tris-HCl (25) . Diffraction was observed using synchrotron radiation at a wavelength between 1.0000-1.2398 Å at the Advanced Light Source (beamline 4.2.2; Berkeley, CA); crystals were flash frozen to 100 K. The lattice contained one TR f dimer per asymmetric unit. The structure was determined by molecular replacement (Supplemental Methods). Of the 86 residues in the refined model of the TR f dimer in the asymmetric unit (excluding 8 Gly, 2 Pro, and 6 end-residues), 79 residues (92%) lie in the most favored Ramachandran region, and 7 residues (8%) in generously allowed regions.
1 H-NMR Spectroscopy-Native self-assembly was prevented by "DKP" substitutions as described (24) . Spectra of [His A4 , His A8 ]-DKPinsulin were acquired in D 2 O at 700 MHz and 25 o C. The analog was made 0.5 mM in 10 mM deuterated Tris-DCl (pD 7.6, direct meter reading) in the presence or absence of equimolar ZnCl 2 .
Receptor Binding Assays-IR (isoform B) and IGF-1R binding assays were performed by a microtiter plate antibody-capture assay (Supplemental Methods) (21) . Wild-type insulin, insulin glargine, and IGF-I provided controls. Data were analyzed by non-linear regression using a 2-site sequential model (21) . The percentage of tracer bound in the absence of competing ligand was <15% to avoid liganddepletion artifacts.
Rodent Assay-Male Lewis rats (mean weight ~300 g) were rendered diabetic by streptozotocin (26 
Results and Discussion
The pI of [His A4 , His A8 ]-insulin was found to be 6.6. Although highly soluble at pH 7.4 in the absence of Zn ions, the analog precipitated at Zn 2+ :insulin molar ratios above 0.4. Solubility was largely regained at pH values >8.5 at room temperature, presumably due to deprotonation of N-terminal α-amino groups. Such precipitation requires native protein assembly as 1 H-NMR studies of an engineered monomeric analog (24) indicated that the paired His element does not bind equimolar Zn 2+ in this context (Supplemental Fig. S2 ). Lattice contacts between wild-type hexamers in insulin crystals provided a model for structural mechanisms of assembly-dependent zinc binding. The proximity of A4 and A8 side chains across such contact surfaces suggested that tetrahedral Zn-binding sites could be formed between successive [His A4 , His A8 ]-insulin hexamers. Novel A4-A8-mediated Zn coordination might therefore be possible near sites of bound interfacial water molecules in wild-type crystal lattices (blue spheres in Fig.  2A , shown in stereo in Supplemental Fig. S3-A) .
To test this hypothesis, we determined the crystal structure of [His A4 , His A8 ]-insulin. Crystals were grown in the presence of Zn 2+ and phenol to yield T 3 R f 3 hexamers (27) . The structure was obtained by molecular replacement at 1.9 Å resolution ( Table 1 ). The analog's mode of hexamer assembly (Fig. 1D ) is identical to that of wild-type insulin (Fig. 1C) . Respective conformations of T and R f protomers are essentially identical to those of wild-type insulin (Supplemental Fig. S4 and Supplemental Table  S1 ). No transmitted perturbations occur at receptor-binding surfaces (4) .
Wild-type and variant hexamers each contain two axial Zn ions, one per T 3 and R f 3 trimer (violet spheres overlaid in Fig. 1C,D) . Coordination at each site is mediated by trimerrelated His B10 side chains with distorted tetrahedral geometry (light gray at center of hexamers in Fig. 2C ,D and Supplemental Table  S2 ). Stereo views of the variant TR f dimer in the asymmetric unit and of the Zn-binding surface of the T protomer are provided in Supplemental Figure S5 . In the R f 3 trimer the fourth ligand is a chloride ion; in the T 3 trimer this site (more exposed than in the R f 3 trimer) exhibits partial occupancy by either a chloride ion or bound water molecule (Supplemental Fig. S6 ). These features are consistent with wild-type structures (27) . As is also observed in wild-type crystals grown under similar conditions, the R S5 ). These novel Zn ions are coordinated in part by His A4 and His A8 at an interfacial site. Representative electron density at the peripheral Zn-binding site defines a distorted tetrahedral site (Fig. 1E , Supplemental Table S2 ). Coordination is completed by a chloride ion and a "stapled" His A4 side chain belonging to an R f protomer of an adjoining hexamer (labeled A4' in Fig. 1E and brown arrows in Fig. 2B) . Views of the opposing T and R f faces of adjoining hexamers are shown in Figure 2C (90 o rotated from the orientation shown in Fig. 2B) . Binding of the chloride ion is stabilized by a network of three water molecules bound to the R f protomer (blue spheres in stereo pairs in Fig. 2D) ; His A8 in R f is displaced from the Zn-binding site. The three non-classical Zn ions thus bridge the T 3 and R online), in part displacing water molecules ordinarily bound at the wild-type interface (blue spheres in Fig. 2A) . N-Zn 2+ bond distances and angles are similar to those of the axial metal-ionbinding sites (Supplemental Table S2 ). Sidechain conformations of His A4 and His A8 differ between T and R f protomers (Supplemental Table S3 ).
Studies of hormone binding to IR and IGF-1R were undertaken to assess relative affinities and receptor-binding selectivity (Fig. 2E and Supplemental Table S4 ). Ligands were characterized as Zn-free monomers. Relative to the binding of human insulin to IR and IGF-IR (solid and dotted green lines in Fig. 2E , respectively), insulin glargine (solid and dotted blue lines) exhibits 2-fold reduced affinity for IR and 3-fold enhanced affinity for IGF-1R. By contrast [His A4 , His A8 ]-insulin exhibits nativelike affinity for IR (solid red line in Fig. 2E ) but 6-fold reduced affinity for IGF-1R (dotted red line shifted to right). Thus, whereas the receptorbinding selectivity of insulin glargine is impaired by ca. 6- A8 ]-insulin were tested in diabetic rats in relation to insulin glargine (Fig. 2F) . Glycemic control by long-acting insulin analogs in rodents (5-10 h) is less prolonged than in humans (18-24 h), presumably due to smaller depot sizes (28) .
[His A4 , His A8 ]-insulin and insulin glargine were dissolved (like Lantus) in dilute HCl (pH 4.0) with a Zn 2+ :insulin ratio of 5.2:1. The time course and extent of glycemic control were similar on injection of the two analogs (red and blue lines in Fig. 2F) . A rapid-acting control was provided by Zn-free human insulin in Lilly diluent (green line in Fig. 2F ). Because the rats ate only at night, effects of daytime insulin injections were influenced by diurnal fasting; controls were provided by injection of diluent alone (brown line in Fig. 2F ). Control studies were also undertaken of [His A4 , His A8 ]-insulin in neutral Zn-free Lilly diluent; its time course was similar to that of wild-type insulin control (not shown). Zn-free glargine was not tested at neutral pH due to its sparing solubility. . Although the present crystal structure provides a model for Zn-bridged self-association surfaces, the number and distribution of bound Zn ions may differ in a non-crystalline aggregate formed on injection. In the future this issue may be addressed by biochemical characterization of the initial subcutaneous depot.
Concluding Remarks. The present study demonstrates the potential of interfacial Znbinding sites, introduced by design (17, 29) , to modify the pharmacokinetics of a protein in a subcutaneous depot. Such bottom-up control of assembly illustrates general principles of supramolecular chemistry and their application to nanobiotechnology (1, 2) .
Optimal treatment of diabetes mellitus often requires combined use of fast-and slow-acting insulin analogs (7, 30) . The principle of isoelectric precipitation underlies the prolonged action of insulin glargine, an analog in broad clinical use (Lantus) (11, 12, 30) . Although slow release of Zn-free monomers enables basal metabolic regulation, concerns have been raised regarding IGF-1R-mediated mitogenicity (14) and possible dose-dependent cancer risk (15, 16 
